|PROJECT TITLE||THE ‘RAPID INTERVENTION WITH GLYCERYL TRINITRATE IN HYPERTENSIVE STROKE TRIAL-2’ (RIGHT-2)|
|Funding body||British Heart Foundation Clinical Study CS/14/4/30972.|
|Overarching aim||The aim of the RIGHT2 trial was to assess the safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, in hyper-acute stroke in the context of a multicentre ambulance-based trial.|
|Methods||Randomised controlled clinical trial|
|The most important expected outcomes of RIGHT2 will be to determine the difference between GTN and no GTN in death, disability, dependency, mood, cognition, and quality of life following stroke.|
Bath PM, Scutt P, Anderson CS, Ankolekar A, Appleton JP, Berge E, Cala L, Dixon M, England TJ, Godolphin PJ, Havard D, Haywood L, Hepburn T, Krishnan K, Mair G, Montgomery AA, Muir K, Phillips SJ, Pocock S, Potter J, Price CI, Randall M, Robinson TG, Roffe C, Rothwell PM, Sandset EC, Sanossian N, Saver JL, Shone A, Siriwardena AN, Wardlaw JM, Woodhouse LJ, Venables G, Sprigg N et al (2019). Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. The Lancet (online first) http://dx.doi.org/10.1016/S0140-6736(19)30194-1.
|Impact||Clinical-medical: a novel treatment for hyper-acute stroke which, if shown to be effective, will change management of stroke worldwide.
Economic: potential for reduction in costs of hospital treatment and long term health and social care from stroke.
Social: potential for prevention of long-term disability and suffering from stroke.